RxDoctor Payments Data

Norman Kier

Primary Care · Sacramento, CANPI 1952912131

Payments from drug & device makers

$2,608in general payments, 2019–2025

Across 96 payments — averaging $27.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$473
  • Amgen$472
  • Novo Nordisk$428
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$378
  • Agios Pharmaceuticals, Inc.$184
  • AbbVie$122
  • plus $551 from 16 others

What the payments were for

  • Food & beverage$2,608100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,608 in reported general payments places this provider in the 85th percentile of 706 primary care providers in California.

See all primary care providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$24,561
EliquisApixaban19$16,053
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,494
JardianceEmpagliflozin14$12,719
LinzessLinaclotide11$5,345
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen100$2,453
BreynaBudesonide/Formoterol Fumarate14$2,137
Naloxone Hcl40$2,069
Albuterol Sulfate HfaAlbuterol Sulfate74$1,822
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,066
Atorvastatin Calcium124$864
Lidocaine11$737
Ventolin HfaAlbuterol Sulfate15$697
Losartan Potassium90$623
Gabapentin70$587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$428$24,56124 claims
PfizerEliquis$59$16,05319 claims
GSKTrelegy Ellipta$15$15,49415 claims
AbbVieLinzess$122$5,34511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 706 primary care providers in California.

Other primary care in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →